PRL and neoplasm: Cabergoline (CAB) has been largely recommended as the first line agent, due to its better tolerability and higher efficacy in normalizing prolactin (PRL) levels and inducing tumor shrinkage, compared to bromocriptine (2, 5, 7, 8).